B. Tait

发表

A novel nonpeptide HIV-1 protease inhibitor: elucidation of the binding mode and its application in the design of related analogs.

C. Humblet, E. Lunney, S. Hagen, 1994, Journal of medicinal chemistry.

5,6-Dihydropyran-2-ones possessing various sulfonyl functionalities: potent nonpeptidic inhibitors of HIV protease.

G. Zeikus, E. Lunney, S. Gulnik, 2000, Journal of medicinal chemistry.

Nonpeptidic HIV protease inhibitors possessing excellent antiviral activities and therapeutic indices. PD 178390: a lead HIV protease inhibitor.

G. Zeikus, C. Humblet, E. Lunney, 1999, Bioorganic & medicinal chemistry.

Pyrazole inhibitors of HMG-CoA reductase: an attempt to dramatically reduce synthetic complexity through minimal analog re-design.

B. Tait, M. Kowala, G. Lu, 2007, Bioorganic & medicinal chemistry letters.

A Rapid Screening Test to Determine the Antioxidant Potencies of Natural and Synthetic Antioxidants.

W. Pryor, B. Tait, D. Witiak, 1993 .

Use of a High-Throughput Phenotypic Screening Strategy to Identify Amplifiers, a Novel Pharmacological Class of Small Molecules That Exhibit Functional Synergy with Potentiators and Correctors

K. Giuliano, B. Tait, J. Miller, 2017, SLAS discovery : advancing life sciences R & D.

Inhibition of Usp14 Stimulates the Proteolytic Degradation and Clearance of Misfolded Proteins Associated with Neurodegenerative Diseases

Anjanabha Saha, D. Garza, K. Giuliano, 2013 .

In silico screening for compounds that match the pharmacophore of omega-hexatoxin-Hv1a leads to discovery and optimization of a novel class of insecticides

Whitney W. Smith, B. Tait, B. Steinbaugh, 2013 .

Management of Hsp90-Dependent Protein Folding by Small Molecule Targeting the Aha1 Co-Chaperone

B. Tait, W. Balch, J. Gestwicki, 2018, bioRxiv.

Novel Series of Achiral, Low Molecular Weight, and Potent HIV-1 Protease Inhibitors

James B. Dunbar, Daniel F. Ortwine, Donna Ferguson, 1994 .

Reversal of .pi.-facial diastereoselection upon electronegative substitution of the substrate and the reagent

Carl R. Johnson, B. Tait, A. Cieplak, 1989 .

Synthesis of 5,6-dihydro-4-hydroxy-2-pyrones as HIV-1 protease inhibitors: the profound effect of polarity on antiviral activity.

E. Lunney, S. Hagen, J. Domagala, 1997, Journal of medicinal chemistry.

A cerium(III) modification of the Peterson reaction: methylenation of readily enolizable carbonyl compounds

Carl R. Johnson, B. Tait, 1987 .

6-Phenyl-6-alkylamido-5,6-dihydro-2H-pyran-2-ones: novel HIV protease inhibitors

E. Lunney, S. Hagen, B. Tait, 1996 .

A rapid screening test to determine the antioxidant potencies of natural and synthetic antioxidants

W. Pryor, B. Tait, D. Witiak, 1993 .

Reversal of π-Facial Diastereoselection Upon Electronegative Substitution of the Substrate and the Reagent.

Carl R. Johnson, B. Tait, A. Cieplak, 1990 .

Discovery of novel hepatoselective HMG-CoA reductase inhibitors for treating hypercholesterolemia: a bench-to-bedside case study on tissue selective drug distribution.

Bo Feng, David B Duignan, Bruce Auerbach, 2011, Bioorganic & medicinal chemistry letters.

Nonpeptide inhibitors of HIV protease

S. Hagen, B. Tait, J. Prasad, 2000 .

Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors.

Yuntao Song, Bruce Auerbach, Lisa Dillon, 2008, Bioorganic & medicinal chemistry letters.

Small Molecule Proteostasis Regulators for Protein Conformational Diseases

Monica A. Chalfant, D. Garza, R. Morimoto, 2011, Nature chemical biology.

SAR Study of the Indole Moiety of CI-988, a Potent and Selective CCK-B Antagonist

B. Tait, B. Roth, M. Wilson, 1997 .

Attenuation of diet‐induced atherosclerosis in rabbits with a highly selective 15‐lipoxygenase inhibitor lacking significant antioxidant properties

R. D. Dyer, B. Tait, A. Daugherty, 1997, British journal of pharmacology.

Effects of some phenothiazines, tricyclic antidepressants and antihistamines on red cell agglutination

B. Tait, 1970, The Journal of pharmacy and pharmacology.

Inhibition of red cell agglutination in the ABO system by promethazine

B. Tait, 1968, The Journal of pharmacy and pharmacology.

Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hypercholesterolemia.

Bruce Auerbach, Lisa Dillon, Jeffrey A Pfefferkorn, 2008, Journal of medicinal chemistry.

Catechol based inhibitors of 15-lipoxygenase

B. Tait, R. Dyer, B. Roth, 1996 .

Nonpeptidic HIV protease inhibitors: 6-alkyl-5,6-dihydropyran-2-ones possessing achiral 3-(4-amino/carboxamide-2-t-butyl,5-methylphenyl thio) moiety: antiviral activities and pharmacokinetic properties.

E. Lunney, S. Hagen, J. Domagala, 1999, Bioorganic & medicinal chemistry letters.

Chapter Twenty - Disease-Modifying Agents for the Treatment of Cystic Fibrosis

B. Tait, J. Miller, 2014 .

Small Molecule Proteostasis Regulators for Protein Conformational Diseases

Monica A. Chalfant, D. Garza, R. Morimoto, 2011, Nature chemical biology.

Management of Hsp90-Dependent Protein Folding by Small Molecules Targeting the Aha1 Co-Chaperone.

B. Tait, W. Balch, J. Gestwicki, 2020, Cell chemical biology.

Hydrophobicity of HIV Protease Inhibitors by Immobilized Artificial Membrane Chromatography: Application and Significance to Drug Transport

O. H. Chan, B. Tait, C. John, 1998, Pharmaceutical Research.

Discovery and optimization of nonpeptide HIV-1 protease inhibitors.

E. Lunney, S. Hagen, J. Domagala, 1996, Bioorganic & medicinal chemistry.

4-hydroxy-5,6-dihydropyrones. 2. Potent non-peptide inhibitors of HIV protease.

C. Humblet, E. Lunney, S. Gulnik, 1997, Journal of medicinal chemistry.